Survival of children with sickle cell disease

Blood

Volumn 103, Issue 11, 2004, Pages 4023-4027

  Quinn, Charles T ^a   Rogers, Zora R ^b   Buchanan, George R ^b  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

AGE; ARTICLE; BETA THALASSEMIA; CALCULATION; CAUSE OF DEATH; CHILD DEATH; COHORT ANALYSIS; DIAGNOSTIC APPROACH ROUTE; FEMALE; FOLLOW UP; HEMOGLOBIN SC DISEASE; HUMAN; INFECTION; MAJOR CLINICAL STUDY; MALE; NEWBORN; NEWBORN SCREENING; PRIORITY JOURNAL; SICKLE CELL ANEMIA; SURVIVAL;

EID: 2542455639     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood-2003-11-3758     Document Type: Article

References (33)

1. Serjeant GR, Serjeant BE. Sickle Cell Disease. 3rd ed. New York, NY: Oxford University Press; 2001.
2. Steinberg MH. Management of sickle cell disease. N Engl J Med. 1999;340:1021-1030.
3. Platt OS, Brambilla DJ, Rosse WF, et al. Mortality in sickle cell disease: life expectancy and risk factors for early death. N Engl J Med. 1994;330:1639-1644.
4. Scott RB. Health care priority and sickle cell anemia. JAMA. 1970;214:731-734.
5. Vichinsky E, Hurst D, Earles A, Kleman K, Lubin B. Newborn screening for sickle cell disease: effect on mortality. Pediatrics. 1988;81:749-755.
6. Vichinsky EP. Comprehensive care in sickle cell disease: its impact on morbidity and mortality. Semin Hematol. 1991;28:220-226.
7. Health supervision for children with sickle cell disease. Pediatrics. 2002;109:526-535.
8. Charache S, Terrin ML, Moore RD, et al. Effect of hydroxyurea on the frequency of painful crises in sickle cell anemia. Investigators of the Multicenter Study of Hydroxyurea in Sickle Cell Anemia. N Engl J Med. 1995;332:1317-1322.
9. Walters MC, Patience M, Leisenring W, et al. Bone marrow transplantation for sickle cell disease. N Engl J Med. 1996;335:369-376.
10. Reed W, Vichinsky EP. Transfusion therapy: a coming-of-age treatment for patients with sickle cell disease. J Pediatr Hematol Oncol. 2001;23:197-202.
11. Gill FM, Sleeper LA, Weiner SJ, et al. Clinical events in the first decade in a cohort of infants with sickle cell disease. Blood. 1995;86:776-783.
12. Lee A, Thomas P, Cupidore L, Serjeant B, Serjeant G. Improved survival in homozygous sickle cell disease: lessons from a cohort study. BMJ. 1995;311:1600-1602.
13. Consensus conference. Newborn screening for sickle cell disease and other hemoglobinopathies. JAMA. 1987;258:1205-1209.
14. Gaston MH, Verter JI, Woods G, et al. Prophylaxis with oral penicillin in children with sickle cell anemia: a randomized trial. N Engl J Med. 1986;314:1593-1599.
15. American Academy of Pediatrics: committee on Infectious Diseases. Red Book: Report of the Committee on Infectious Diseases. 26th ed. Elk Grove Village, IL: American Academy of Pediatrics; 2003.
16. Therrell BL Jr, Brown LO, Dziuk PE, Peter WP Jr. The Texas Newborn Screening Program. Tex Med. 1983;79:44-46.
17. Therren BL Jr, Simmank JL, Wilborn M. Experiences with sickle hemoglobin testing in the Texas Newborn Screening Program. Pediatrics. 1989;83:864-867.
18. Cox DR, Oakes D. Analysis of Survival Data. London, United Kingdom: Chapman and Hall; 1984.
19. Bemini JC, Mustafa MM, Sutor LJ, Buchanan GR. Fatal hemolysis induced by ceftriaxone in a child with sickle cell anemia. J Pediatr. 1995;126:813-815.
20. Assanasen C, Quinton RA, Buchanan GR. Acute myocardial infarction in sickle cell anemia. J Pediatr Hematol Oncol. 2003;25:978-981.
21. Davis H, Gergen PJ, Moore RM. Geographic differences in mortality of young children with sickle cell disease in the United States. Public Health Rep. 1997;112:52-58.
22. Davis H, Schoendorf KC, Gergen PJ, Moore RM. National trends in the mortality of children with sickle cell disease, 1968 through 1992. Am J Public Health. 1997;87:1317-1322.
23. Leikin SL, Gallagher D, Kinney TR, Sloane D, Klug P, Rida W. Mortality in children and adolescents with sickle cell disease. Cooperative Study of Sickle Cell Disease. Pediatrics. 1989;84:500-508.
24. Powars DR. Natural history of sickle cell disease-the first ten years. Semin Hematol. 1975;12:267-285.
25. Powars DR, Hiti A, Ramicone E, Johnson C, Chan L. Outcome in hemoglobin SC disease: a four-decade observational study of clinical, hematologic, and genetic factors. Am J Hematol. 2002;70:206-215.
26. Murthy VK, Haywood LJ. Survival analysis by sex, age group and hemotype in sickle cell disease. J Chronic Dis. 1981;34:313-319.
27. Serjeant GR, Serjeant BE, Forbes M, Hayes RJ, Higgs DR, Lehmann H. Haemoglobin gene frequencies in the Jamaican population: a study in 100,000 newborns. Br J Haematol. 1986;64:253-262.
28. Powars D, Chan LS, Schroeder WA. The variable expression of sickle cell disease is genetically determined. Semin Hematol. 1990;27:360-376.
29. Falletta JM, Woods GM, Verter JI, et al. Discontinuing penicillin prophylaxis in children with sickle cell anemia. Prophylactic Penicillin Study II. J Pediatr. 1995;127:685-690.
30. Thomas AN, Pattison C, Serjeant GR. Causes of death in sickle-cell disease in Jamaica. BMJ. 1982;285:633-635.
31. Ohene-Frempong K, Weiner SJ, Sleeper LA, et al. Cerebrovascular accidents in sickle cell disease: rates and risk factors. Blood. 1998;91:288-294.
32. Balkaran B, Char G, Morris JS, Thomas PW, Serjeant BE, Serjeant GR. Stroke in a cohort of patients with homozygous sickle cell disease. J Pediatr. 1992;120:360-366.
33. Horan J, Lerner N. Prediction of adverse outcomes in children with sickle cell disease. N Engl J Med. 2000;342:1612-1613.